ABSTRACT
Background Research on the impact of the PEPFAR transition in South Africa (SA) in 2012 found varying results in retention in care (RIC) of people living with HIV (PLWH).
Objectives We investigated the factors that impacted RIC during the U.S. President’ s Emergency Plan for AIDS Relief (PEPFAR) transition in Western Cape, South Africa in 2012.
Methods We used aggregate data from 61 facilities supported by four non-governmental organizations from to 2007-2015. The main outcome was RIC at 12-months after antiretroviral therapy initiation for two time periods. We used quantile regression to estimate the effect of the PEPFAR pull-out and other predictors on RIC. The models were adjusted for various covariates.
Results Regression models (50th quantile) for 12-month RIC showed a 4.6% (95%CI: -8.4, - 0.8%) decline in RIC post direct service. Facilities supported by Anova/Kheth’ impilo fared worst post PEFPAR; a decline in RIC of (−5.8%; 95% CI: -9.7, -1.8%), while that’ sit fared best (6.3% increase in RIC; 95% CI:2.5,10.1%). There was a decrease in RIC when comparing urban to rural areas (−5.8%; 95% CI: -10.1, -1.5%). City of Cape town combined with Western Cape Government Health facilities showed a substantial decrease (−9.1%; 95% CI: -12.3, -5.9%), while community health clinic (vs. primary health clinic) declined slightly (−4.4; 95% CI: -9.6, 0.9%) in RIC. We observed no RIC difference by facility size and a slight increase when two or more human resources transitioned from PEPFAR to the government.
Conclusions When PEPFAR funding decreased in 2012, there was a decrease in RIC. To ensure the continuity of HIV care when a major funder withdraws sufficient and stable transition resources, investment in organizations that understand the local context, joint planning, and coordination are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ATB was funded by the National Institute of Diabetes and Digestive and Kidney Diseases 1K01DK116929-01A1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The author(s) of this article are solely responsible for the content.
Email: abrennan{at}bu.edu, Email: richardl{at}bu.edu, Email: ffeeley{at}bu.edu
Source(s) of support/funding: ATB was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1K01DK116929-01A1.
Disclosure of relationships and activities (ie, conflict of interests): The authors have no conflicts of interest.
The incorrect K01 grant was referenced in the funding section. It has been updated to reference the following grant 1K01DK116929-01A1.
Data Availability
All data produced in the present work are contained in the manuscript
